Evidence map›Paper›PMID 27586014›Full record

ArticleSurgery today2017

Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.

Hideo Tomihara, Hidetoshi Eguchi, Daisaku Yamada, Kunihito Gotoh, Koichi Kawamoto, Hiroshi Wada, Tadafumi Asaoka, Takehiro Noda, Yutaka Takeda, Masahiro Tanemura and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Application ofOncotarget · 2019
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hideo TomiharaDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hidetoshi EguchiDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan. heguchi@gesurg.med.osaka-u.ac.jp.
Daisaku YamadaDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Kunihito GotohDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Koichi KawamotoDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hiroshi WadaDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tadafumi AsaokaDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Takehiro NodaDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yutaka TakedaDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Masahiro TanemuraDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Masaki MoriDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuichiro DokiDepartment of Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Osaka University · JPOsaka Police Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePreoperative chemoradiotherapy (CRT) is a novel, emerging treatment strategy for pancreatic ductal adenocarcinoma (PDAC), but it remains unclear whether post-surgery adjuvant chemotherapy is feasible following preoperative CRT. This retrospective study evaluates the feasibility of adjuvant therapy after preoperative CRT.

methodsThe subjects of this study were 99 consecutive patients who underwent pancreatectomy for PDAC between January, 2007 and February, 2013 in our hospital. Sixty patients received preoperative CRT: as gemcitabine (GEM) and 40 Gy radiation in 28 (G-CRT group), and as GEM, S-1, and 50.4 Gy radiation in 32 (GS-CRT group). We also evaluated 39 patients who underwent surgery alone (SA group). We investigated adjuvant chemotherapy induction and completion rates and the frequency of adverse events rated ≥grade 3, based on Common Terminology Criteria for Adverse Events (version 4.0) in all three groups.

resultsIn the G-CRT, GS-CRT, and SA groups, the induction rates were 78 % (22/28), 78 % (25/32), and 72 % (28/39), respectively; completion rates were 86 % (19/22), 88 % (22/25), and 82 % (23/28), respectively; and adverse event frequencies were 36 % (8/22), 28 % (7/25), and 43 % (12/28), respectively. No significant difference was found among the three groups.

conclusionPreoperative CRT was demonstrated to be safe and did not compromise the feasibility of adjuvant chemotherapy.

Indexed as

Chemoradiotherapy, AdjuvantPancreatectomyAdenocarcinomaAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantCombined Modality TherapyDeoxycytidineDrug CombinationsFeasibility StudiesFemaleGemcitabineHumansMaleDeoxycytidineDrug CombinationsGemcitabineOxonic AcidS 1 (combination)TegafurAdverse eventNeoadjuvant chemotherapyPancreatic ductal adenocarcinomaPreoperative chemoradiotherapy

Identifiers

PMID27586014
OpenAlexW2510636274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.